Visual analogue scale (VAS) as a monitoring tool for daily changes in asthma symptoms in adolescents: a prospective study by Rhee, Hyekyun (Author) et al.
Rhee et al.  
Allergy Asthma Clin Immunol  (2017) 13:24 
DOI 10.1186/s13223-017-0196-7
RESEARCH
Visual analogue scale (VAS) as a 
monitoring tool for daily changes in asthma 
symptoms in adolescents: a prospective study
Hyekyun Rhee1* , Michael Belyea2 and Jennifer Mammen1
Abstract 
Background: Success in asthma management hinges on patients’ competency to detect and respond to ever-
changing symptom severity. Thus, it is crucial to have reliable, simple, and sustainable methods of symptom monitor-
ing that can be readily incorporated into daily life. Although visual analogue scale (VAS) has been considered as a 
simple symptom assessment method, its utility as a daily symptom monitoring tool in adolescents is unknown. This 
study was to determine the concurrent validity of VAS in capturing diurnal changes in symptoms and to examine the 
relationships between VAS and asthma control and pulmonary function.
Methods: Forty-two adolescents (12–17 years old) with asthma completed daily assessment of symptoms twice 
per day, morning and bedtime, for a week using VAS and 6-item symptom diary concurrently. Asthma control was 
measured at enrollment and 6 month later, and spirometry was conducted at enrollment. Pearson correlations, multi-
level modeling and regression were conducted to assess the relationships between VAS and symptom diary, asthma 
control and FEV1.
Results: Morning and evening VAS was positively associated with symptom diary items of each corresponding time 
frame of the day (r = 0.41–0.58, p < 0.0001). Morning VAS was significantly predicted by morning diary data reflecting 
nocturnal wakening (β = 2.13, p = 0.033) and morning symptoms (β = 4.09, p = 0.002), accounting for 57% of the 
total variance of morning VAS. Similarly, changes in four evening diary items, particularly shortness of breath (β = 2.60, 
p = 0.028), significantly predicted changes in evening VAS, accounting for 55% of the total variance. Average VAS 
scores correlated with asthma control (r = 0.65, p < 0.001) and FEV1 (r = −0.38, p = 0.029), and were predictive of 
asthma control 6 months later (β = 0.085, p = 0.006).
Conclusions: VAS is a valid tool capturing diurnal changes in symptoms reflected in a multi-item symptom diary. 
Moreover, VAS is a valid measure predicting concurrent and future asthma control. The findings suggest VAS can be a 
simple alternative to daily dairies for daily symptom monitoring, which can provide invaluable information about cur-
rent and future asthma control without substantially increasing self-monitoring burdens for adolescent patients.
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Background
Asthma symptom monitoring incorporated in daily rou-
tines is essential to successful asthma self-management 
[1–3]. Symptom monitoring is linked to fewer cases 
of asthma exacerbation and acute care visits, as well as 
better functional outcomes and higher quality of life in 
children and adolescents [4]. Recognition of symptoms 
through monitoring allows patients to take necessary 
management actions (e.g., adjusting medication, altering 
activity level, avoiding or minimizing triggers, or seek-
ing assistance). Moreover, patients’ symptom monitoring 
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is an essential source of information in implementing 
guideline based treatment.
Expert Panel Report 3 (EPR-3) by the National Heart, 
Lung and Blood Institute [3] recommends that each 
patient be taught to recognize symptom patterns indi-
cating inadequate asthma control. The need for a patient 
completed monitoring tool that can capture the variabil-
ity and changing nature of asthma between office visits 
has been recognized [5, 6]. To address the need, symp-
tom diaries have been suggested especially for those with 
uncontrolled or persistent asthma, as it can aid in the 
identification of asthma of higher severity [3, 7]. Asthma 
diaries completed on a daily basis minimize recollection 
errors [8], and are a better means for identifying patients 
with persistent asthma compared to retrospective reports 
of usually previous 4 weeks, as in a periodic self-assess-
ment form completed at the time of an office visit (e.g., 
asthma control test) [7].
Structured daily diaries often consist of multiple items 
assessing various symptoms and asthma related impair-
ments, which can be burdensome to children and ado-
lescents, resulting in poor adherence. This calls for an 
alternative symptom monitoring strategy that is simple 
and conducive to daily use by young patients. A visual 
analogue scale (VAS) can be the alternative to multiple 
item diaries for daily symptom monitoring. VAS has been 
found useful in assessing patient’s subjective experience 
or perception of a variety of clinical phenomena [9]. VAS 
scores have been shown to be associated with varying 
levels of asthma control [10–12] and pulmonary function 
[11, 12]. A simple VAS performed better in capturing 
asthma severity compared to other structured assess-
ment methods of multiple categories measuring the same 
construct [13]. For being a single item with minimal 
wording, VAS requires little time or literacy to complete. 
These advantages render VAS suitable for daily use for 
symptom monitoring, particularly in pediatric patients.
The extent to which the VAS performs as an alternative 
to multiple item diaries for a daily symptom assessment 
tool for adolescents remains to be explored. In particu-
lar, demonstrating its capacity to capture diurnal and 
day-to-day variations in symptoms would be critical to be 
considered as a symptom monitoring tool. The purpose 
of this study was to determine the concurrent validity of 
VAS in capturing diurnal changes in symptoms and to 
examine the relationships between VAS and asthma con-
trol and pulmonary function.
Methods
Study sample and setting
This study was the secondary analysis of data origi-
nally collected for a study that examined the valid-
ity of a newly developed automated device monitoring 
asthma symptoms [14]. Eligibility criteria included age 13 
through 17, having physician-diagnosed asthma at least 
1 year, and ability to understand spoken and written Eng-
lish. Those with other diagnoses producing asthma-like 
symptoms (e.g., cardiac disease and cystic fibrosis) were 
excluded. Subjects were recruited from the pediatric 
emergency department (ED) and outpatient clinics (pri-
mary practice and pediatric pulmonary specialty clinic) 
in a major university medical center located in the North-
eastern U.S. Of a total of 42 participants, the majority 
(69%) were recruited from the emergency department, 
and the remaining were from the study flyers (24%) and 
clinician referrals (8%).
Study measures
Visual analogue scale (VAS)
The VAS was 100  mm long with 3 anchors dividing 3 
zones (green, yellow, and red). For each symptom, the 
green zone (0–20  mm) labeled “no symptoms”, the yel-
low zone (21–50  mm) “mild symptoms” and the red 
zone (50–100 mm) “very bad symptoms” [13, 15]. Teens 
marked any point on the zone according to their percep-
tion of symptoms. The distance between the 0 mm mark 
and the placement of the “X” was measured to provide 
a numeric interpretation of their symptom perception. 
VAS was used twice, morning (VAS-am) and bedtime 
(VAS-pm).
Asthma Control Diary (ACD)
This 6-item diary measures the levels of symptoms on a 
7-point scale from zero (no symptom) to 6 for consistent 
symptoms [16]. The diary data were collected electroni-
cally using an iPod to increase participants’ adherence 
and convenience. By sending automatic reminders and 
restricting the time of entry, the electronic diaries were 
useful in ascertaining adherence and reinforcing proper 
entry time, thereby reducing the recollection bias and 
risk of fabrication. Morning questions (2 items) pertained 
to nocturnal wakening and morning symptoms, and bed-
time questions (4-items) assessed the degree of activity 
limitation, shortness of breath, and wheeze they experi-
enced during the day and use of short-acting beta agonist 
(SABA) in previous 24 h. Each item was evaluated sepa-
rately in the analysis.
Forced expiratory volume in one second (FEV1)
Spirometry test  (KoKo®: Pulmonary Data Service; Lou-
isville, CO, USA) was conducted on the first day of the 
7-day trial to obtain FEV1 in accordance with the Ameri-
can Thoracic Society standards [17].
Asthma control questions consisting of 4 questions were 
devised for the study based on four impairment based 
asthma control criteria provided by EPR3. The criteria 
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including the frequency of the limitation of daily activity, 
nocturnal wakening, asthma symptoms and use of SABA 
in the past 4  weeks were measured on a 5-point scale. 
Asthma control questions were administered at enroll-
ment and at the 6-months follow-up. A total score was 
computed; higher scores indicating poor asthma control.
Demographic and asthma-related information was col-
lected, including gender, age, race, annual family income, 
years with asthma diagnosis and current medications.
Data collection procedure
Institutional Review Board within the academic insti-
tution affiliated with the principal investigator (HR) 
reviewed and approved the study for human subject 
protection. Informed consent was obtained from par-
ents and assent from adolescents prior to data col-
lection. At enrollment, a demographic form, asthma 
control questions and spirometry were administered. 
Adolescents completed a paper form VAS twice a 
day, morning and bedtime, for 7  days. Simultane-
ously, electronic asthma diaries were completed using 
an iPod programed to push morning and evening 
questions at the designated timeframes each day for 
7 days. Automatic reminders were sent until the com-
pletion of scheduled diary questions  within the time-
frame. Asthma control questions were repeated at the 
6-month follow up.
Data analysis
Pearson correlations were computed to assess the rela-
tionships between VAS and ACD, asthma control and 
FEV1. A multilevel regression model for longitudinal data 
was used to assess the relationships between VAS and 
daily asthma symptoms reported in ACD measured twice 
a day for seven consecutive days. Morning and even-
ing VAS measures were analyzed using two hierarchical 
models: (1) a model with time varying covariates, and 
(2) a final model with the addition of the demographic 
covariates. Diary symptoms were grand mean centered, 
where 0 represented the average level of the measure, and 
entered simultaneously into the model.
In the first model, asthma symptoms as time-varying 
predictors of VAS were entered into the model. In these 
models, VAS was modeled with an intercept, linear slope, 
and with the time-varying covariates entered simulta-
neously (nocturnal wakening and morning symptoms 
for morning VAS and activity limitation, shortness of 
breath, wheezing, and SABA use for evening VAS). Using 
daily asthma symptoms as time-varying covariates tests 
whether they can explain changes in the overall trajec-
tory of VAS. Such tests would examine whether VAS and 
asthma symptoms measured at the within-person level 
changed together.
In the second model, age, sex, and race were entered as 
time fixed demographic variables. The introduction of time 
fixed covariates tests whether the association between VAS 
and asthma symptoms persists after controlling for the 
demographic variables. Multilevel regression analysis, using 
all available data from each participant, was conducted 
using the Mixed procedure in SAS. Ordinary least squares 
regression analysis was conducted to examine the extent to 
which VAS predicted asthma control after 6  months. All 
statistical analyses were conducted in SAS (v.9.3). The level 
of significance was set at p < 0.05 for all tests.
Results
Forty-two adolescents (mean age 15.2  years; SD  =  1.5) 
participated: 60% (n = 25) females, 57% (n = 24) minority 
and 52% (n = 22) with annual household income less than 
$30,000. Based on the EPR-3 classification criteria, 36% 
(n = 15) and 33% (n = 14) of the sample reported not well 
controlled and very poorly controlled asthma, respectively.
Correlations between VAS and Asthma Control Diary 
Questions
The relationships between average VAS for morn-
ing and evening and each time-corresponding diary 
data obtained for 7  days were examined in 41 persons. 
One participant’s electronic diary data were lost due to 
unknown technical glitches. Table  1 displays the sum-
mary of correlation coefficients between VAS and each 
of items of ACD. Significant correlations were found 
between VAS and ACD, ranging from r = 0.41 to 0.58.
Morning VAS and morning diary variables
Table 2 displays the descriptive statistics of morning VAS 
(VAS-am) data over 7 days.
Multilevel regression models for the 7 measurement 
points were conducted. Model 1 (Table 3) was computed 
to examine the relationship between VAS-am and two 
morning diary items, nocturnal wakening and bad morn-
ing symptoms, as time varying covariates.




 Nocturnal wakening 0.45***
 Morning symptoms 0.55***
Evening diary items
 Activity limitation 0.41***
 Shortness of breath 0.52***
 Wheezing 0.58***
 Short acting beta agonist use 0.42***
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The average starting or initial level of morning VAS was 
18.13 (t =  8.35, p =  0.001). The linear slope (time) was 
not significant indicating that the level of reported VAS-
am was relatively stable for each individual for 7 days as a 
whole. However, tests of the random effects indicated sig-
nificant individual differences in the intercepts or starting 
values for VAS-am (z  =  3.73, p  <  0.0001) and individ-
ual differences in its slopes or linear change over time 
approached significance (z = 1.46, p < 0.07). Changes in 
nocturnal wakening (β =  2.21, p =  0.024) and morning 
symptoms (β = 3.79, p = 0.002) were significantly related 
to changes in morning VAS. Including age, gender and 
race as covariates (Model 2, Table  3) did not substan-
tially change these relationships. Approximately 57% of 
the total variance of VAS-am scores was accounted for by 
Model 2.
Evening VAS and evening diary variables
Table 4 displays the means and distributions for evening 
VAS (VAS-pm) over 7 days.
Model 1 examined the relationship between VAS-pm 
and the evening diary variables of limited activity, short-
ness of breath, wheeze, and SABA use as time varying 
covariates. Model 1 (Table 5), indicates that on average, 
the starting or initial level of VAS-pm for participants 
was 18.58. The linear trend for the group as a whole was 
not significant indicating that the overall average VAS-
pm was relatively stable.
Shortness of breath had a significant effect on VAS-pm 
(β = 2.27, p = 0.04) after controlling for other items, such 
that changes in shortness of breath predicted changes in 
VAS-pm scores above and beyond other evening diary 
items. Wheezing approached significance. Including age, 
gender, and race as covariates (Model 2) further reduced 
the effect of wheezing, but did not change the relation-
ship between shortness of breath and VAS-pm. Females 
reported higher VAS-pm. The total variance accounted 
for in VAS-pm scores by Model 2 was approximately 55%.
VAS and asthma control and FEV1
Adjusting for age, gender and race, average VAS scores 
from 7  days correlated with asthma control questions 
(r =  0.65, p  < 0.001) and FEV1 (r = −0.38, p =  0.029). 
Average VAS was predictive of asthma control at 
6  months (β  =  0.085, p  =  0.006) after controlling for 
age, gender and race. VAS along with demographic vari-
ables accounted for 33% of variance of asthma control at 
6-months.
Table 2 Descriptive statistics for morning VAS
Time point N Mean SD Skewness Kurtosis Range
VAS Day 1 34 19.18 19.85 1.69 2.95 0–82
VAS Day 2 41 18.41 16.77 1.20 0.91 0–63
VAS Day 3 41 18.95 19.82 1.79 3.25 0–84
VAS Day 4 41 16.98 15.50 1.09 0.84 0–65
VAS Day 5 41 15.93 17.24 1.87 3.86 0–75
VAS Day 6 41 17.05 17.50 1.17 0.48 0–64
VAS Day 7 41 15.59 15.21 0.70 −0.96 0–50
Average 41 17.33 14.58 0.79 −0.49 0–50.71
Table 3 Morning VAS predicted by the morning diary items as time varying covariates
Model 1 Model 2
Standard Standard
Estimate SE p Estimate SE p
Effect
 Intercept 18.13 2.17 ≤.001 −0.70 −0.70 0.974
 Time −0.24 0.33 0.479 −0.32 0.34 0.360
 Nocturnal wakening 2.21 0.98 0.024 2.13 0.99 0.033
 Morning symptoms 3.79 1.20 0.002 4.09 1.29 0.002
 Age 0.81 1.34 0.557
 Sex (1 = female) 5.18 4.25 0.224
 Race (1 = non-white) 5.77 4.26 0.177
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Discussion
This study demonstrates that VAS can be a reason-
able alternative to symptom diaries for daily symptom 
monitoring in adolescents with asthma. To our knowl-
edge, this is the first study to provide evidence for VAS’ 
capacity to reflect diurnal and daily variation in asthma 
symptoms. In an earlier cross-sectional study, VAS 
appropriately differentiated between good, usual and 
bad breathing days in children with asthma [18]. A pro-
spective study also supported VAS as an instrument that 
could reasonably detect symptom variations between 
two discrete observation points with 2  weeks apart in 
adult patients with allergic rhinitis [19]. Our findings 
provide more specific evidence that VAS can capture 
symptom fluctuations occurring not only day-to-day but 
also within each day.
Consistent with earlier studies [11, 20, 21], we found 
moderate correlation between VAS and pulmonary 
function, supporting VAS as a tool for measuring air-
way obstruction. Validity and clinical usefulness of VAS 
has often been evaluated in comparison to an objective 
assessment of airway obstruction such as FEV1. Studies 
have shown correlations between the degrees of symp-
toms indicated on VAS and FEV1 in adults [12, 22] and 
children with asthma [11, 23]. The relationships between 
VAS and pulmonary function do not appear to be 
affected by age and gender of children [11]. In fact, symp-
tom perception measured on VAS reliably correlated 
with pulmonary function in children with asthma across 
a broad age ranging from 5 to 15 years [24]. Furthermore, 
in an earlier study [21], VAS was able to discriminate 
children with bronchial obstruction (FEV1  <80% pre-
dicted) from those with normal lung function through 
the demonstration of significant group differences in 
VAS scores at a single point. Also, changes in symptom 
perceptions after use of bronchodilator in children with 
asthma were also adequately captured by VAS, which was 
suggestive of bronchial reversibility [21]. Based on the 
evidence, the authors advocated for the potential appli-
cation of VAS in establishing an asthma diagnosis in the 
absence of spirometer in some office settings [21]. Over-
all, accumulated evidence including ours is overwhelm-
ingly in favor of VAS of symptom perception as a proxy 
measure of airway obstruction.
Table 4 Descriptive statistics for evening VAS
Time point N Mean Std D Skewness Kurtosis Range
VAS Day 1 41 18.80 19.82 1.77 3.30 0–87
VAS Day 2 40 19.83 21.13 1.84 4.12 0–100
VAS Day 3 41 20.95 20.36 1.24 0.95 0–77
VAS Day 4 40 17.98 17.20 1.49 2.45 0–75
VAS Day 5 40 15.10 15.13 1.31 1.33 0–63
VAS Day 6 41 18.05 17.84 1.18 0.89 0–74
VAS Day 7 41 18.37 17.37 1.08 0.65 0–70
Average 41 18.44 15.83 1.00 0.27 0–62.86
Table 5 Evening VAS predicted by the evening diary items as time varying covariates
Model 1 Model 2
Standard Standard
Estimate SE p Estimate SE p
Effect
 Intercept 18.58 2.83 <0.001 −19.62 19.10 0.311
 Time −0.13 0.49 0.795 −0.08 0.52 0.874
 Activity limitation 0.11 0.89 0.904 0.21 0.93 0.821
 Shortness of breath 2.27 1.11 0.042 2.60 1.18 0.028
 Wheezing 2.27 1.20 0.060 2.11 1.24 0.089
 SABA use −0.45 1.67 0.786 −0.95 1.67 0.571
 Age 1.97 1.21 0.104
 Sex (1 = female) 9.00 3.81 0.019
 Race (1 = non-white) 3.41 3.83 0.375
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As in a previous study [25], we found a moderate to 
strong correlation between VAS and symptom control. 
It is important to recognize that traditional measures of 
symptom control often fail to capture the full extent of 
symptoms, particularly in adolescent populations, result-
ing in underestimation of symptoms [26, 27]. Therefore, 
the lack of decisive correlation between VAS and a con-
ventional measure of asthma control should not be inter-
preted as an indication of inadequacy of the VAS. On the 
contrary, it is equally likely that unexplained variance 
between the VAS and the conventional asthma control 
measure may have been due to the conventional meas-
ure’ limited capacity to fully represent the construct of 
symptom control. Nonetheless, demonstrated correla-
tions between VAS and symptom diary items were close 
to or well above 0.5, indicating large effect size [28]. Simi-
lar to our findings, a large cross-sectional epidemiologi-
cal study of nearly 30,000 adult patients demonstrated 
that VAS measured symptom severity accurately and 
predicted asthma control as defined by Global Initiative 
for Asthma [10]. This earlier study also showed no differ-
ences in VAS scores between patient-rated versus physi-
cian-rated, supporting the reproducibility of the measure 
across different raters. Furthermore, we found that VAS 
was predictive of asthma control 6 months later. To our 
knowledge, this is the first study providing the evidence 
of predictive validity of VAS longitudinally. The possi-
bility of gauging future asthma morbidity using simple 
VAS has important clinical implications as it could help 
patients and clinicians determine plans for long-term 
treatment.
Taken all together, VAS scores could be a simple, reli-
able indicator of asthma control in adolescents, when 
used daily. VAS is easily understood and can be a useful 
tool in improving children’s perceptual ability [29]. How-
ever, there are mixed reports regarding when VAS would 
be useful and valid in asthma monitoring. Some reported 
that VAS more adequately measured symptom control 
when severity is low [20, 30]. Given that accuracy of 
symptom perception in children and adolescents shows 
a marked decrease when symptom severity elevates [27, 
31], perhaps VAS may be more appropriate for those with 
intermittent to mild severity. Conversely, others provided 
evidence demonstrating VAS to be more useful in those 
with moderate to severe asthma [12] or airway obstruc-
tion (FEV1  <80%) [11]. Similarly, in another study [32] 
VAS scores reflected peak exploratory flow rates more 
adequately when children experienced actual symptoms 
compared to symptom-free times, hence supporting use 
of VAS only for moderate to severe cases of asthma. In 
order for VAS to be considered as a daily symptom moni-
toring tool, however, it is essential that it be sufficiently 
sensitive to wide range of symptom severity from low 
to high. Although this study offers a glimpse of the pos-
sibility that VAS could capture the broader spectrum of 
symptom severity, further research is required to provide 
more conclusive evidence in a large sample of adoles-
cents with differing levels of symptom control.
VAS is a simple and straightforward method to assess 
daily variations of asthma symptoms and the degrees of 
asthma control and airway obstruction. The simplicity 
makes the measure less dependent on users’ literacy or 
attention capability and requires very little time to com-
plete. Nonetheless, by allowing responses to vary along 
the line of continuum, VAS could adequately assess and 
quantify subtle changes in an individual’s perception 
about a subjective attribute such as symptoms over time 
[9, 33]. Evidence that VAS effectively captured positive 
changes in asthma condition responding to bronchodila-
tion [21] provides further support for the tool’s usefulness 
in assessing treatment effects and preventing overestima-
tion of asthma control through improved symptom per-
ception [34]. These benefits render VAS a practical daily 
symptom assessment tool that can potentially maximize 
users’ long-term compliance, through which symptom 
perception can be improved and asthma morbidity can 
be prevented or detected at an earlier stage.
This study is subject to several limitations germane 
to the study design. First, a small convenient sample of 
adolescents with asthma limits the generalizability of the 
findings. It is also worth mentioning that despite a large 
portion of our sample having been recruited from the 
emergency department, average VAS scores were gener-
ally low indicating mild symptoms albeit with wide vari-
ations. In USA, low income families tend to use the ED 
for usual asthma care or management that could have 
been handled at primary care practices [35, 36]. Hence, 
ED visits do not always suggest higher symptom sever-
ity in such populations. A large-scale study using a sam-
ple representing a broad spectrum of symptom severity 
is warranted to assure the replicability of our findings 
prior to broad clinical implementation of VAS as a symp-
tom monitoring tool. Second, our relatively brief obser-
vation period (7  days) prevented us from establishing 
the validity of VAS for an extended period during which 
symptom variations may become more pronounced. 
Third, we were unable to assess changes in VAS scores 
responding to treatment (e.g., short-term vs. long-term 
medication) during the observation period. Strategi-
cally timed administration of VAS before and after spe-
cific medication is needed to assess the usefulness of 
VAS as a tool capturing treatment effect. In addition, it 
is unclear whether and how VAS could be used to dis-
criminate different levels of asthma control correspond-
ing to the EPR3 guidelines. Such information might have 
provided further compelling evidence supporting the 
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clinical utility of VAS. Lastly, this study relied primarily 
on a symptom diary against which changes in VAS scores 
were compared. Given adolescents’ poor perception of 
asthma symptoms [27, 37, 38], the sole reliance on the 
symptom diary may raise a question of validity. To date 
existing daily symptom monitoring is predominantly 
self-report in nature. Therefore, comparing one measure 
of self-report (symptom diary) to another (VAS) is justi-
fied to make a case for comparability between two moni-
toring methods. Nonetheless, further research, such as 
comparison with daily peak flow, is needed to augment 
the adequacy of VAS as a daily monitoring tool. Use of 
VAS in conjunction with peak flow monitoring has been 
reported to increase symptom perception and medica-
tion adherence [39]. Moreover, research establishing the 
criterion validity of VAS by examining its correlations 
with airway inflammation (e.g., nitric oxide) and disease 
burden (e.g., asthma exacerbation, acute healthcare utili-
zation or school absenteeism) is warranted.
Despite the identified limitations, this study has impor-
tant clinical implications. Demonstrated correlations 
between the VAS and a daily symptom assessment and an 
asthma control measure suggest that the single-item VAS 
be a viable alternative to multiple-question, multiple-
choice methods. Inability to identify day to day variations 
in symptoms often presents challenges for appropriate 
clinical decision-making. Current retrospective recall 
methods or multi-item symptom diaries have been found 
inadequate, due to recall bias or poor patient compliance. 
In contrast, VAS is a simple, one-step solution to current 
practice of symptom monitoring, and has the potential 
to aid tracking daily symptoms in real time without sub-
stantially increasing burdens for patients.
Conclusions
Success in asthma management hinges on patients’ com-
petency to detect and respond to ever-changing symp-
tom severity. Thus, it is crucial to have valid and simple 
methods of symptom assessment that can be readily 
incorporated into daily life with minimal patient or pro-
vider burden. This study supports VAS as the simplest 
possible symptom tracking tool for adolescents in ambu-
latory settings. Future research is warranted to determine 
the effectiveness and long-term sustainability of VAS and 
to explore the extent to which daily VAS would facilitate 
patients’ self-management and providers’ clinical decision 
making (e.g. medication management). To enhance daily 
accessibility and adherence, VAS digital versions down-
loaded onto smart phones can be considered. This will not 
only facilitate real time, long-term symptom tracking and 
increase its appeal to adolescent patients but also holds 
potential for integration with electronic medical records, 
enhancing clinical usefulness of VAS data.
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